RecruitingNCT05387369
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
Sponsor
Huashan Hospital
Enrollment
2,000 participants
Start Date
Mar 21, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
Eligibility
Min Age: 12 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Paxlovid for people with covid-19. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPaxlovid
The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05387369
Related Trials
Patient-Centered Practical Vaccine Talk For Busy Clinicians
NCT076517611 location
Serological and PCR Testing for COVID-19
NCT044040621 location
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection
NCT052421591 location
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
NCT076551801 location
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
NCT075363086 locations